Tianshui Zhongxing Bio-Technology (002772.SZ): Signed an investment promotion contract with the Lianshui County People's Government. The total project investment is 0.55 billion yuan.

On November 26, Gelonghui reported that tianshui zhongxing bio-technology (002772.SZ) announced that based on the company's global strategy of "rooted in the northwest, facing the whole country, and moving towards the world" for its production base layout, as well as the planting variety development strategy of "focusing on enoki mushrooms and button mushrooms, with multi-variety collaborative development," to further consolidate and enhance the market share of the company's button mushroom products, the company intends to sign an "investment attraction contract" with the Lianshui County People's Government, and plans to invest in the establishment of a wholly-owned subsidiary, jiangsu tianshui zhongxing bio-technology technology Co., Ltd. (tentative name, subject to the information registered by market supervision and management departments) to construct and implement the "Lianshui edible mushroom industry.

Gelonghui FinanceNov 26 04:14 ET

Tianshui Zhongxing Bio-technology Plans Up to 150-Million-Yuan Share Buyback

MT NewswiresNov 15 04:14 ET

Earnings Troubles May Signal Larger Issues for Tianshui Zhongxing Bio-technologyLtd (SZSE:002772) Shareholders

Simply Wall StNov 1 20:10 ET

Zhongxing Bacteria: Report for the third quarter of 2024

SZSIOct 25 12:00 ET · Announcements

tianshui zhongxing bio-technology (002772.SZ) released performance for the first three quarters, with a net income of 88.65 million yuan, a year-on-year decrease of 49.49%.

tianshui zhongxing bio-technology (002772.SZ) disclosed the third quarter report of 2024, achieving revenue in the first three quarters of 14...

Zhitong FinanceOct 25 11:13 ET

Tianshui Zhongxing Bio-Technology (002772.SZ): the net income for the first three quarters was 88.6507 million yuan, a decrease of 49.49% year-on-year.

On October 25, Gelonhui reported that tianshui zhongxing bio-technology (002772.SZ) released its third-quarter report. In the first three quarters of 2024, the company achieved revenue of 1.416 billion yuan, a 2.48% year-on-year decrease; the net income attributable to shareholders of the listed company was 88.6507 million yuan, a 49.49% year-on-year decrease; the net income after deducting non-recurring gains and losses was 65.4606 million yuan, a 58.47% year-on-year decrease; and the basic earnings per share was 0.2254 yuan per share.

Gelonghui FinanceOct 25 11:11 ET